Related Experiment Video
Updated: May 30, 2025

Induction of an Inflammatory Response in Primary Hepatocyte Cultures from Mice
Published on: March 10, 2017
Role of serum fibroblast growth factor-23 and Klotho level in COVID-19 infection-related mortality: a prospective
Davut Akin1, Burcu B Aydogan2, Nilufer Emre3
1Department of Nephrology, Pamukkale University School of Medicine, Denizli,Turkey.
Insights
Elevated fibroblast growth factor 23 (FGF23) and lower Klotho levels are linked to higher mortality in hospitalized COVID-19 patients without chronic kidney disease. These biomarkers, along with age and oxygen saturation, predict mortality risk.
Area of Science:
- Biochemistry and Molecular Biology
- Infectious Diseases
- Nephrology
Background:
- Investigated the role of fibroblast growth factor 23 (FGF23)/Klotho in COVID-19 mortality.
- Excluded patients with chronic kidney disease (CKD).
Purpose of the Study:
- To determine the association between FGF23/Klotho levels and mortality in hospitalized COVID-19 patients without CKD.
- To identify independent predictors of mortality in this patient cohort.
Main Methods:
- Prospective cross-sectional study from April 2021 to May 2022.
- Classified 66 COVID-19 patients into survivors and non-survivors.
- Analyzed demographic data, clinical status, prognosis, and serum biomarkers including FGF23, Klotho, and Vitamin D.
Main Results:
- Non-survivors were significantly older and had higher FGF23 levels compared to survivors.
- Elevated FGF23, older age, and lower oxygen saturation at admission were independent predictors of mortality.
- Lower Klotho levels were observed in non-survivors, while Vitamin D levels showed no significant difference.
Conclusions:
- Elevated serum FGF23 and lower Klotho levels are associated with COVID-19-related mortality in patients without CKD.
- Serum Vitamin D levels were not associated with mortality in this cohort.
- Further research is needed to elucidate the complex relationships between FGF23/Klotho, PTH, Vitamin D, and COVID-19 mortality.
Introduction:
This study investigated the role of fibroblast growth factor 23 (FGF23)/Klotho in the mortality of patients hospitalized with coronavirus disease 2019 (COVID-19), excluding those with chronic kidney disease (CKD).
Methodology:
A prospective cross-sectional study was conducted from April 2021 to May 2022. Patients who tested positive for COVID-19 via polymerase chain reaction and were hospitalized, were classified into two groups (survivors and non-survivors) at the end of their hospital follow-up. Demographic data, clinical status, and prognosis were analyzed.
Results:
A total of 66 patients (age 58.8 ± 17.0 years, 60.6% male) were included. The mean age of non-survivors (67.2 ± 1 years) was significantly higher than the survivors (49.2 ± 1 years; p < 0.0001). FGF23 was significantly elevated in non-survivors (301 ± 20 pg/mL), compared to survivors (160 ± 36 pg/mL; p < 0.0001). Factors with significant differences (p < 0.001) between the two groups were investigated as independent mortality predictors using logistic regression analysis. FGF23 (p = 0.01), age (p = 0.045), and oxygen saturation at admission (p = 0.02) were independent predictors of mortality. High serum FGF23 levels were associated with COVID-19-related mortality; Klotho levels were lower (p = 0.028). Vitamin D was not significantly different between the groups.
Conclusion:
Elevated serum FGF23 and parathyroid hormone (PTH), and lower Klotho levels, were associated with COVID-19-related mortality in patients without CKD. There was no association with serum vitamin D levels. Further studies are required to establish the relationship between mortality and FGF23/Klotho, PTH, and vitamin D levels.
Related Concept Videos
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Introduction to Fibroblasts

